Utilization of hepatitis B core antibody-positive donor liver grafts

HPB

Volumn 14, Issue 1, 2012, Pages 42-48

  MacConmara, Malcolm P ^a   Vachharajani, Neeta ^a   Wellen, Jason R ^a   Anderson, Christopher D ^a   Lowell, Jeffrey A ^a   Shenoy, Surendra ^a   Chapman, William C ^a   Doyle, Maria B Majella ^a  

^a WASHINGTON UNIVERSITY   (United States)

Author keywords

Donor; Hepatitis B; Liver transplantation

Indexed keywords

ADEFOVIR; ANTIVIRUS AGENT; ENTECAVIR; HEPATITIS B ANTIBODY; HEPATITIS B CORE ANTIBODY; LAMIVUDINE; VIRUS DNA;

ADULT; AGED; ARTICLE; BODY MASS; CAUSE OF DEATH; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE COURSE; FEMALE; GRAFT FAILURE; GRAFT SURVIVAL; HEPATITIS B; HEPATITIS C; HUMAN; INFECTION RISK; KAPLAN MEIER METHOD; LIVER DISEASE; LIVER TRANSPLANTATION; MALE; MORBIDITY; MORTALITY; MULTIPLE ORGAN FAILURE; ORGAN DONOR; ORGAN TRANSPLANTATION; OVERALL SURVIVAL; PREOPERATIVE EVALUATION; RETROSPECTIVE STUDY; SEPSIS; SEROLOGY; TREATMENT OUTCOME; VIRUS HEPATITIS;

EID: 83555174856     PISSN: 1365182X     EISSN: 14772574     Source Type: Journal    
DOI: 10.1111/j.1477-2574.2011.00399.x     Document Type: Article

References (19)

1. Manzarbeitia C, Reich DJ, Ortiz JA, Rothstein KD, Araya VR, Munoz SJ,. (2002) Safe use of livers from donors with positive hepatitis B core antibody. Liver Transpl 8: 556-561. (Pubitemid 34619089)
2. Cholongitas E, Papatheodoridis GV, Burroughs AK,. (2010) Liver grafts from anti-hepatitis B core positive donors: a systematic review. J Hepatol 52: 272-279.
3. Muñoz SJ,. (2002) Use of hepatitis B core antibody-positive donors for liver transplantation. Liver Transpl 8 (10 Suppl. 1): 82-87.
4. Marugán RB, García-Hoz F, Romero MV, Nash R, Mateos M, Alonso RG, et al,. (2002) Prevention of de novo hepatitis B infection in liver allograft recipients with previous hepatitis B infection or hepatitis B vaccination. Am J Gastroenterol 97: 2398-2401.
5. Dickson RC, Everhart JE, Lake JR, Wei Y, Seaberg EC, Wiesner RH, et al,. (1997) Transmission of hepatitis B by transplantation of livers from donors positive for antibody to hepatitis B core antigen. The National Institute of Diabetes and Digestive and Kidney Diseases Liver Transplantation Database. Gastroenterology 113: 1668-1674. (Pubitemid 27461255)
6. Dodson SF, Issa S, Araya V, Gayowski T, Pinna A, Eghtesad B, et al,. (1997) Infectivity of hepatic allografts with antibodies to hepatitis B virus. Transplantation 64: 1582-1584. (Pubitemid 28047387)
7. Roque-Afonso AM, Feray C, Samuel D, Simoneau D, Roche B, Emile JF, et al,. (2002) Antibodies to hepatitis B surface antigen prevent viral reactivation in recipients of liver grafts from anti-HBc positive donors. Gut 50: 95-99. (Pubitemid 34028310)
8. Perrillo R,. (2009) Hepatitis B virus prevention strategies for antibody to hepatitis B core antigen-positive liver donation: a survey of North American, European, and Asian-Pacific transplant programmes. Liver Transpl 15: 223-232.
9. Jankowska I, Pawlowska J, Teisseyre M, Kaliciński P, Kamiński A, Czubkowski P, et al,. (2007) Prevention of de novo hepatitis B virus infection by vaccination and high hepatitis B surface antibodies level in children receiving hepatitis B virus core antibody-positive living related donor liver: case reports. Transplant Proc 39: 1511-1512. (Pubitemid 46907876)
10. Prieto M, Gõmez MD, Berenguer M, Cõrdoba J, Rayõn JM, Pastor M, et al,. (2001) De novo hepatitis B after liver transplantation from hepatitis B core antibody-positive donors in an area with high prevalence of anti-HBc positivity in the donor population. Liver Transpl 7: 51-58. (Pubitemid 32060915)
11. Yu L, Koepsell T, Manhart L, Ioannou G,. (2009) Survival after orthotopic liver transplantation: the impact of antibody against hepatitis B core antigen in the donor. Liver Transpl 15: 1343-1350.
12. Wasley A, Kruszon-Moran D, Kuhnert W, Simard EP, Finelli L, McQuillan G, et al,. (2010) The prevalence of hepatitis B virus infection in the United States in the era of vaccination. J Infect Dis 202: 192-201.
13. United Network for Organ Sharing (UNOS). OPTN/SRTR Annual Report 2008. http://optn.transplant.hrsa.gov [Accessed 1 March 2011.]
14. Saab S, Waterman B, Chi AC, Tong MJ,. (2010) Comparison of different immunoprophylaxis regimens after liver transplantation with hepatitis B core antibody-positive donors: a systematic review. Liver Transpl 16: 300-307.
15. Nery JR, Nery-Avila C, Reddy KR, Cirocco R, Weppler D, Levi DM, et al,. (2003) Use of liver grafts from donors positive for antihepatitis B-core antibody (anti-HBc) in the era of prophylaxis with hepatitis-B immunoglobulin and lamivudine. Transplantation 75: 1179-1186. (Pubitemid 36513018)
16. Bárcena R, Campo SD, Moraleda G, Casanovas T, Prieto M, Buti M, et al,. (2005) Study on the efficacy and safety of adefovir dipivoxil treatment in post-liver transplant patients with hepatitis B virus infection and lamivudine-resistant hepatitis B virus. Transplant Proc 37: 3960-3962. (Pubitemid 43015223)
17. Prakoso E, Strasser SI, Koorey DJ, Verran D, McCaughan GW,. (2006) Longterm lamivudine monotherapy prevents development of hepatitis B virus infection in hepatitis B surface-antigen negative liver transplant recipients from hepatitis B core-antibody-positive donors. Clin Transplant 20: 369-373. (Pubitemid 43880574)
18. Burton JR, Shaw-Stiffel TA,. (2003) Use of hepatitis B core antibody-positive donors in recipients without evidence of hepatitis B infection: a survey of current practice in the United States. Liver Transpl 9: 837-842. (Pubitemid 36974951)
19. Jimenez-Perez M, Saez-Gomez AB, Mongil Poce L, Lozano-Rey JM, de la Cruz-Lombardo J, Rodrigo-Lopez JM,. (2010) Efficacy and safety of entecavir and/or tenofovir for prophylaxis and treatment of hepatitis B recurrence post-liver transplant. Transplant Proc 42: 3167-3168.